<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2024-13-4-1924</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1945</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ И КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL AND CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Кросс-валидация методик количественного определения феназепама и его активного метаболита в плазме крови человека при различной экстракции</article-title><trans-title-group xml:lang="en"><trans-title>Cross-validation of methods for the quantitative determination of phenazepam and its active metabolite in human blood plasma at various extractions</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9682-4623</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Платова</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Platova</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 34</p></bio><bio xml:lang="en"><p>34, Kashirskoe shosse, Moscow, 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9326-4683</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмин</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzmin</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 34</p></bio><bio xml:lang="en"><p>34, Kashirskoe shosse, Moscow, 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2295-7167</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иващенко</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivaschenko</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>125993, г. Москва, ул. Баррикадная, д. 2/1</p></bio><bio xml:lang="en"><p>2/1, Barrikadnaya str., Moscow, 125993</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4950-5336</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мирошниченко</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Miroshnichenko</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 34</p></bio><bio xml:lang="en"><p>34, Kashirskoe shosse, Moscow, 115522</p></bio><email xlink:type="simple">igormir41@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное государственное бюджетное научное учреждение «Научный центр психического здоровья» (ФГБНУ НЦПЗ)<country>Россия</country></aff><aff xml:lang="en">Federal State Budgetary Scientific Institution "Mental Health Research Center"<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Russian Medical Academy of Continuous Professional Education<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>11</day><month>10</month><year>2024</year></pub-date><volume>13</volume><issue>4</issue><fpage>212</fpage><lpage>222</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Платова А.И., Кузьмин И.И., Иващенко Д.В., Мирошниченко И.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Платова А.И., Кузьмин И.И., Иващенко Д.В., Мирошниченко И.И.</copyright-holder><copyright-holder xml:lang="en">Platova A.I., Kuzmin I.I., Ivaschenko D.V., Miroshnichenko I.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1945">https://www.pharmjournal.ru/jour/article/view/1945</self-uri><abstract><sec><title>Введение</title><p>Введение. При проведении терапевтического лекарственного мониторинга (ТЛМ) часто возникает ситуация, когда концентрацию лекарственного средства измеряют разными методами или в разных лабораториях. Для объединения и анализа данных, полученных с помощью разных методов, необходимо выполнять перекрестную валидацию (кросс-валидацию). Применяемым для этого статистическим подходам уделяется недостаточное внимание.</p></sec><sec><title>Цель</title><p>Цель. Выполнить кросс-валидацию разных методик количественного определения феназепама (ФЕН) и 3-гидроксифеназепама (3-ОН-ФЕН) с помощью анализа Бленда – Альтмана.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Концентрации ФЕН и 3-ОН-ФЕН в плазме крови пациентов (n = 100) c синдромом отмены алкоголя были измерены с помощью высокоэффективной жидкостной хроматографии с тандемной масс-спектрометрией (ВЭЖХ-МС/МС). В каждом образце содержание обоих аналитов измеряли двукратно с помощью двух разных методик: твердофазной экстракции (SPE, от англ. «solid phase extraction») и жидкостной экстракции с поддержкой (SLE, от англ. «supported liquid extraction»). Обе методики до начала эксперимента прошли полную валидацию. Кросс-валидация проводилась по завершении эксперимента с использованием данных от испытуемых образцов. Для оценки правильности (accuracy) и прецизионности (precision) использовали анализ Бленда – Альтмана. Для выявления систематической ошибки между методиками также применяли регрессионный анализ Деминга.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Для обоих аналитов были получены регрессионные зависимости между концентрациями, измеренными разными методами пробоподготовки. 95%-й доверительный интервал (ДИ) коэффициентов обоих уравнений включал единицу, а 95%-й ДИ свободного члена включал ноль. 95%-й ДИ геометрического среднего индивидуальных отношений SLE/SPE находился в пределах допустимого диапазона (0,87; 1,15). Данные результаты подтверждают отсутствие влияния количественной методики на измерение концентрации обоих аналитов. 66,7%-й ДИ относительной погрешности между двумя измерениями находился в допустимых пределах (–0,2; 0,2), не превышая 20%-й диапазон от их среднего значения. Это подтверждает приемлемую прецизионность между методиками. Вычисленные доверительные интервалы отражены на диаграммах аналитического смещения по Бленду – Альтману.</p></sec><sec><title>Заключение</title><p>Заключение. Применяемые в работе статистические подходы подтвердили сопоставимость результатов разных методик пробоподготовки. Описанный в работе статистический алгоритм с применением диаграмм аналитического смещения по Бленду – Альтману, помимо кросс-валидации, может успешно применяться для оценки правильности и прецизионности при валидации и оценке приемлемости аналитического цикла, а также при повторном анализе испытуемых образцов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. In conducting of therapeutic drug monitoring (TDM), often such situation arises where the drug concentration has measured by different methods or in different laboratories. To combine and analyze the data obtained with different methods, it is necessary to perform cross-validation procedure. Insufficient attention is paid to the statistical approaches used for this purpose.</p></sec><sec><title>Aim</title><p>Aim. Performing cross-validation of different analytical methods for the quantitative determination of phenazepam (PHEN) and 3-hydroxyphenazepam (3-OH-PHEN) using the Bland – Altman analysis.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. PHEN and 3-OH-PHEN concentrations in the blood plasma of patients (n = 100) with alcohol withdrawal syndrome were measured using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). The quantification of both analytes in each sample was measure twice by two different methods: solid phase extraction (SPE) and supported liquid extraction (SLE). Both methods have been fully validated before the experiment began. Cross-validation was performed at the end of the experiment using data from study samples. The Bland – Altman analysis was used to evaluate accuracy and precision. Deming regression was also used to identify a systematic error between measurement results.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The regression equations have been obtained between concentrations both analytes measured by different sample preparation methods. 95 % confidence intervals (CI) of the regression coefficients of both equations included one, and 95 % CI of the intercepts included zero. 95 % CI of the geometric mean of the individual SLE/SPE ratios was within the acceptable range (0.87; 1.15). These results confirm the absence of the influence of quantitative methods on the measurement of both analytes concentration. 66.7 % CI of the percent difference between two measurements was within acceptable limits (–0.2; 0.2), not exceeding 20 % of the range of their mean value. This confirms the acceptable precision between the methods. The estimated CIs were displayed in the Bland – Altman plots.</p></sec><sec><title>Conclusion</title><p>Conclusion. The statistical approaches used in the work have confirmed the reproducibility of the results of different sample preparation methods. In addition to cross-validation, the statistical algorithm from this paper using Bland – Altman analysis can be successfully employed to assess accuracy and precision during bioanalytical method validation and evaluation of the acceptance of analytical runs, as well as to determine the level of reproducibility of incurred samples.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>феназепам</kwd><kwd>3-оксифеназепам</kwd><kwd>хроматография</kwd><kwd>масс-спектрометрия</kwd><kwd>кросс-валидация</kwd><kwd>метод Бленда – Альтмана</kwd><kwd>регрессия Деминга</kwd><kwd>правильность</kwd><kwd>прецизионность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>phenazepam</kwd><kwd>3-oxyphenazepam</kwd><kwd>chromatography</kwd><kwd>mass spectrometry</kwd><kwd>cross validation</kwd><kwd>Bland Altman analysis</kwd><kwd>Deming regression</kwd><kwd>accuracy</kwd><kwd>precision</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Раменская Г. В., Шохин И. Е., Савченко А. Ю., Давыдова К. С., Кукес В. Г. Обзор требований к валидации биоаналитических методик. Ремедиум. 2011;12:60–63.</mixed-citation><mixed-citation xml:lang="en">Ramenskaya G. V., SHohin I. E., Savchenko A. Yu., Davidova K. S., Kukes V. G. Comparative requirements to validation of bioanalytical methods. Remedium. 2011;12:60–63. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Эпштейн Н. А. Валидация аналитических методик: графические и расчетные критерии для оценки линейности методик на практике. Разработка и регистрация лекарственных средств. 2019;8(2):122–130. DOI: 10.33380/2305-2066-2019-8-2-122-130.</mixed-citation><mixed-citation xml:lang="en">Epshtein N. A. Validation of Analytical Procedures: Graphic and Calculated Criteria for Assessment of Methods Linearity in Practice. Drug development &amp; registration. 2019;8(2):122–130. (In Russ.) DOI: 10.33380/2305-2066-2019-8-2-122-130.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Briggs R. J., Nicholson R., Vazvaei F., Busch J., Mabuchi M., Mahesh K. S., Brudny-Kloeppel M., Weng N., Galvinas P. A. R., Duchene P., Hu P., Abbott R. W. Method transfer, partial validation, and cross validation: recommendations for best practices and harmonization from the global bioanalysis consortium harmonization team. The AAPS Journal. 2014;16(6):1143–1148. DOI: 10.1208/s12248-014-9650-3.</mixed-citation><mixed-citation xml:lang="en">Briggs R. J., Nicholson R., Vazvaei F., Busch J., Mabuchi M., Mahesh K. S., Brudny-Kloeppel M., Weng N., Galvinas P. A. R., Duchene P., Hu P., Abbott R. W. Method transfer, partial validation, and cross validation: recommendations for best practices and harmonization from the global bioanalysis consortium harmonization team. The AAPS Journal. 2014;16(6):1143–1148. DOI: 10.1208/s12248-014-9650-3.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bioanalytical Method Validation. Guidance for Industry. FDA. Biopharmaceutics; 2018. 44 p.</mixed-citation><mixed-citation xml:lang="en">Bioanalytical Method Validation. Guidance for Industry. FDA. Biopharmaceutics; 2018. 44 p.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Городничев А. В., Костюкова Е. Г. Место феназепама в современном применении бензодиазепиновых транквилизаторов. Современная Терапия Психических Расстройств. 2011;2:26–29.</mixed-citation><mixed-citation xml:lang="en">Gorodnichev A. V., Kostyukova E. G. The place of phenazepam in modern use of benzodiazepine tranquilizers. Current Therapy of Mental Disorders. 2011;2:26–29. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Syrjanen R., Greene S. L., Weber C., Smith J. L., Hodgson S. E., Abouchedid R., Gerostamoulos D., Maplesden J., Knott J., Hollerer H., Rotella J.-A., Graudins A., Schumann J. L. Characteristics and time course of benzodiazepine-type new psychoactive substance detections in Australia: results from the Emerging Drugs Network of Australia – Victoria project 2020–2022. International Journal of Drug Policy. 2023;122:104245. DOI: 10.1016/j.drugpo.2023.104245.</mixed-citation><mixed-citation xml:lang="en">Syrjanen R., Greene S. L., Weber C., Smith J. L., Hodgson S. E., Abouchedid R., Gerostamoulos D., Maplesden J., Knott J., Hollerer H., Rotella J.-A., Graudins A., Schumann J. L. Characteristics and time course of benzodiazepine-type new psychoactive substance detections in Australia: results from the Emerging Drugs Network of Australia – Victoria project 2020–2022. International Journal of Drug Policy. 2023;122:104245. DOI: 10.1016/j.drugpo.2023.104245.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Акимова В. Д., Барсегян С. С., Плетенева Т. В. Персонифицированный характер токсических эффектов на примере массовых несмертельных отравлений феназепамом и другими психоактивными веществами. Судебно-медицинская экспертиза. 2024;67(1):47–55.</mixed-citation><mixed-citation xml:lang="en">Akimova V. D., Barsegyan S. S., Pleteneva T. V. Personalized character of toxic effects through mass nonlethal poisoning by phenazepam and psychoactive substances. Forensic Medical Expertise. 2024;67(1):47–55. (In Russ.) DOI: 10.17116/sudmed20246701147.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина Т. А. Ларионов В. Б., Головенко Н. Я., Неробкова Л. Н., Гайдуков И. О. Роль 3-оксиметаболита феназепама и леваны в реализации их нейротропного действия. Фармакокинетика и фармакодинамика. 2014;1:44–49.</mixed-citation><mixed-citation xml:lang="en">Voronina T. A. Larionov V. B., Golovenko N. Ya., Nerobkova L. N., Gaidukov I. O. Role of 3-oximetabolite phenazepam and levan in realize their neurotropic efficacy. Pharmacokinetics and Pharmacodynamics. 2014;1:44–49. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ivashchenko D. V., Rudik A. V., Poloznikov A. A., Nikulin S. V., Smirnov V. V., Tonevitsky A. G., Bryun E. A., Sychev D. A. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metabolism and Personalized Therapy. 2018;33(2):65–73. DOI: 10.1515/dmpt-2017-0036.</mixed-citation><mixed-citation xml:lang="en">Ivashchenko D. V., Rudik A. V., Poloznikov A. A., Nikulin S. V., Smirnov V. V., Tonevitsky A. G., Bryun E. A., Sychev D. A. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metabolism and Personalized Therapy. 2018;33(2):65–73. DOI: 10.1515/dmpt-2017-0036.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zastrozhin M. S., Skryabin V. Yu., Sorokin A. S., Petukhov A. E., Smirnov V. V., Pankratenko E. P., Grishina E. A., Ryzhikova K. A., Panov A. S., Savchenko L. M., Bryun E. A., Sychev D. A. CYP3A subfamily activity affects the equilibrium concentration of Phenazepam® in patients with anxiety disorders and comorbid alcohol use disorder. Pharmacogenomics. 2020;21(7):449–457. DOI: 10.2217/pgs-2019-0071.</mixed-citation><mixed-citation xml:lang="en">Zastrozhin M. S., Skryabin V. Yu., Sorokin A. S., Petukhov A. E., Smirnov V. V., Pankratenko E. P., Grishina E. A., Ryzhikova K. A., Panov A. S., Savchenko L. M., Bryun E. A., Sychev D. A. CYP3A subfamily activity affects the equilibrium concentration of Phenazepam® in patients with anxiety disorders and comorbid alcohol use disorder. Pharmacogenomics. 2020;21(7):449–457. DOI: 10.2217/pgs-2019-0071.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Мирошниченко И. И., Платова А. И., Кузьмин И. И., Иващенко Д. В. Количественное определение феназепама и его активного метаболита в плазме крови человека при различных процедурах экстракции. Разработка и регистрация лекарственных средств. 2024;13(3):199–207. DOI: 10.33380/2305-2066-2024-13-3-1609.</mixed-citation><mixed-citation xml:lang="en">Miroshnichenko I. I., Platova A. I., Kuzmin I. I., Ivaschenko D. V. Quantitative determination of phenazepam and its active metabolite in human blood plasma at different extraction procedures. Drug development &amp; registration. 2024;13(3):199–207. (In Russ.) DOI: 10.33380/2305-2066-2024-13-3-1609.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bland J. M., Altman D. G. Statistical methods for assessing agreement between two methods of clinical measurement. The lancet. 1986;1(8476):307–310.</mixed-citation><mixed-citation xml:lang="en">Bland J. M., Altman D. G. Statistical methods for assessing agreement between two methods of clinical measurement. The lancet. 1986;1(8476):307–310.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rocci M. L., Devanarayan V., Haughey D. B., Jardieu P. Confirmatory reanalysis of incurred bioanalytical samples. The AAPS Journal. 2007;9(3):E336–E143.</mixed-citation><mixed-citation xml:lang="en">Rocci M. L., Devanarayan V., Haughey D. B., Jardieu P. Confirmatory reanalysis of incurred bioanalytical samples. The AAPS Journal. 2007;9(3):E336–E143.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kelley M. Incurred sample reanalysis: it is just a matter of good scientific practice. Bioanalysis. 2011;3(9):931–932. DOI: 10.4155/bio.10.215.</mixed-citation><mixed-citation xml:lang="en">Kelley M. Incurred sample reanalysis: it is just a matter of good scientific practice. Bioanalysis. 2011;3(9):931–932. DOI: 10.4155/bio.10.215.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kringle R. O. An assessment of the 4-6-20 rule for acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. Pharmaceutical research. 1994;11(4):556–560. DOI: 10.1023/a:1018922701174.</mixed-citation><mixed-citation xml:lang="en">Kringle R. O. An assessment of the 4-6-20 rule for acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. Pharmaceutical research. 1994;11(4):556–560. DOI: 10.1023/a:1018922701174.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Giavarina D. Understanding Bland Altman analysis. Biochemia Medica. 2015;25(2):141–151. DOI: 10.11613/BM.2015.015.</mixed-citation><mixed-citation xml:lang="en">Giavarina D. Understanding Bland Altman analysis. Biochemia Medica. 2015;25(2):141–151. DOI: 10.11613/BM.2015.015.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Eastwood B. J., Farmen M. W., Iversen P. W., Craft T. J., Smallwood J. K., Garbison K. E., Delapp N. W., Smith G. F. The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies. Journal of Biomolecular Screening. 2006;11(3):253–261. DOI: 10.1177/1087057105285611.</mixed-citation><mixed-citation xml:lang="en">Eastwood B. J., Farmen M. W., Iversen P. W., Craft T. J., Smallwood J. K., Garbison K. E., Delapp N. W., Smith G. F. The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies. Journal of Biomolecular Screening. 2006;11(3):253–261. DOI: 10.1177/1087057105285611.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kocur A., Rubik J., Czarnowski P., Czajkowska A., Marszałek D., Sierakowski M., Górska M., Pawiński T. Therapeutic drug monitoring of mycophenolic acid (MPA) using volumetric absorptive microsampling (VAMS) in pediatric renal transplant recipients: ultra-high-performance liquid chromatography-tandem mass spectrometry analytical method development, cross-validation, and clinical application. Pharmacological Reports. 2023;75(4):1026–1042. DOI: 10.1007/s43440-023-00509-w.</mixed-citation><mixed-citation xml:lang="en">Kocur A., Rubik J., Czarnowski P., Czajkowska A., Marszałek D., Sierakowski M., Górska M., Pawiński T. Therapeutic drug monitoring of mycophenolic acid (MPA) using volumetric absorptive microsampling (VAMS) in pediatric renal transplant recipients: ultra-high-performance liquid chromatography-tandem mass spectrometry analytical method development, cross-validation, and clinical application. Pharmacological Reports. 2023;75(4):1026–1042. DOI: 10.1007/s43440-023-00509-w.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mano Yu. Method validation studies and an inter-laboratory cross validation study of lenvatinib assay in human plasma using LC-MS/MS. Practical Laboratory Medicine. 2018;12:e00103. DOI: 10.1016/j.plabm.2018.e00103.</mixed-citation><mixed-citation xml:lang="en">Mano Yu. Method validation studies and an inter-laboratory cross validation study of lenvatinib assay in human plasma using LC-MS/MS. Practical Laboratory Medicine. 2018;12:e00103. DOI: 10.1016/j.plabm.2018.e00103.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Marin C., Khoudour N., Millet A., Lebert D., Bros P., Thomas F., Ternant D., Lacarelle B., Guitton J., Ciccolini J., Blanchet B. Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals. 2021;14(8):796. DOI: 10.3390/ph14080796.</mixed-citation><mixed-citation xml:lang="en">Marin C., Khoudour N., Millet A., Lebert D., Bros P., Thomas F., Ternant D., Lacarelle B., Guitton J., Ciccolini J., Blanchet B. Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals. 2021;14(8):796. DOI: 10.3390/ph14080796.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wickremsinhe E. R., Decker R. L., Lee L. B., Lelle E., Carlton L. A., Keller S. Y., Prakash A. Microsampling in pediatric studies: pharmacokinetic sampling for baricitinib (Olumiant™) in global pediatric studies. Bioanalysis. 2023;15(11):621–636. DOI: 10.4155/bio-2023-0044.</mixed-citation><mixed-citation xml:lang="en">Wickremsinhe E. R., Decker R. L., Lee L. B., Lelle E., Carlton L. A., Keller S. Y., Prakash A. Microsampling in pediatric studies: pharmacokinetic sampling for baricitinib (Olumiant™) in global pediatric studies. Bioanalysis. 2023;15(11):621–636. DOI: 10.4155/bio-2023-0044.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer J. A., DeChenne S., Foerder C. A., Hengel S. M. Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis. Bioanalysis. 2022;14(22):1443–1452. DOI: 10.4155/bio-2022-0199.</mixed-citation><mixed-citation xml:lang="en">Meyer J. A., DeChenne S., Foerder C. A., Hengel S. M. Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis. Bioanalysis. 2022;14(22):1443–1452. DOI: 10.4155/bio-2022-0199.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Peris-Vicente J., Esteve-Romero J., Carda-Broch S. Validation of analytical methods based on chromatographic techniques: An overview. In: Anderson J. L., Berthod A., Estévez V. P., Stalcu A. M., editors. Analytical Separation Science. Weinheim: Wiley-VCH Verlag GmbH &amp; Co. KGaA; 2015. P. 1757–1808. DOI: 10.1002/9783527678129.assep064.</mixed-citation><mixed-citation xml:lang="en">Peris-Vicente J., Esteve-Romero J., Carda-Broch S. Validation of analytical methods based on chromatographic techniques: An overview. In: Anderson J. L., Berthod A., Estévez V. P., Stalcu A. M., editors. Analytical Separation Science. Weinheim: Wiley-VCH Verlag GmbH &amp; Co. KGaA; 2015. P. 1757–1808. DOI: 10.1002/9783527678129.assep064.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Yang C., Liu Z., Fang Y., Cao X., Xu G., Wang Z., Hu Z., Wang S., Wu X. Development and validation of a clinic machine-learning nomogram for the prediction of risk stratifications of prostate cancer based on functional subsets of peripheral lymphocyte. Journal of Translational Medicine. 2023;21(1):465. DOI: 10.1186/s12967-023-04318-w.</mixed-citation><mixed-citation xml:lang="en">Yang C., Liu Z., Fang Y., Cao X., Xu G., Wang Z., Hu Z., Wang S., Wu X. Development and validation of a clinic machine-learning nomogram for the prediction of risk stratifications of prostate cancer based on functional subsets of peripheral lymphocyte. Journal of Translational Medicine. 2023;21(1):465. DOI: 10.1186/s12967-023-04318-w.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
